Ionis Pharmaceuticals, Inc. filings document an operating biotechnology company focused on RNA-targeted medicines, marketed products, partnered programs, and clinical-stage pipeline assets. Form 8-K reports cover GAAP and non-GAAP financial results, product-sales updates, Regulation FD disclosures, clinical data releases, and regulatory communications involving programs such as zilganersen in Alexander disease and bepirovirsen in chronic hepatitis B.
Proxy materials describe annual meeting procedures, director matters, board governance, and stockholder voting items. Other filings record capital-structure events and material agreements, including the completed private offering of convertible senior notes due 2030, along with exhibit filings and related corporate disclosures.
Ionis Pharmaceuticals (IONS) officer Shannon Devers reported a proposed sale of 1,357 common shares, with an aggregate market value of $59,708. The notice lists October 16, 2026, as the approximate sale date and names Morgan Stanley Smith Barney as broker. The shares were acquired as compensation through RSUs granted under the 2011 Equity Incentive Plan.
Ionis Pharmaceuticals (IONS) and partner Roche reported positive prespecified interim results from the Phase 3 IMAgINATION study of investigational sefaxersen in adults with primary IgA nephropathy. The study met its primary endpoint, with statistically significant and clinically meaningful proteinuria reductions versus placebo at 37 weeks, measured by 24-hour urine protein-to-creatinine ratio.
The study will continue blinded to assess kidney-function change over two years, measured by estimated glomerular filtration rate at week 105. It enrolled 459 people randomized 1:1 to sefaxersen or placebo for 105 weeks. Sefaxersen is designed as a once-monthly injection for self-administration; no new safety signals were identified. Roche licensed sefaxersen from Ionis, which received upfront, license-fee and development-milestone payments and is eligible for regulatory and sales milestones and tiered royalties on net sales.
Ionis Pharmaceuticals, Inc. (IONS) reported that its partner Novartis’ Phase 3 Lp(a)HORIZON cardiovascular outcomes trial of pelacarsen in patients with elevated lipoprotein(a) did not meet its primary endpoint of reducing major cardiovascular events versus placebo. The composite endpoint covered cardiovascular death, non-fatal myocardial infarction, non-fatal stroke and urgent coronary revascularization requiring hospitalization.
Pelacarsen continued to show substantially lower Lp(a) levels and an acceptable safety profile, and full data are planned for presentation at an upcoming medical congress. Ionis discovered and conducted early development of pelacarsen before Novartis licensed global development and commercialization rights in 2019.
Ionis Pharmaceuticals, Inc. (IONS) announced that the U.S. FDA has approved ZANVASTRO™ (zilganersen) as the first and only disease‑modifying treatment for Alexander disease (AxD) in pediatric and adult patients. ZANVASTRO is an RNA‑targeted therapy given as a 50 mg intrathecal injection every 12 weeks to reduce glial fibrillary acidic protein (GFAP) production. The approval was supported by a pivotal global Phase 1‑3 study that met its primary endpoint, showing statistically significant and clinically meaningful stabilization of gait speed versus control at Week 61, with a favorable safety and tolerability profile. With this approval, Ionis received a Rare Pediatric Disease Priority Review Voucher and plans to launch ZANVASTRO in the U.S. in the coming weeks while partner Recordati prepares regulatory submissions in Europe and Japan, expected in 2027.
IONIS PHARMACEUTICALS INC executive Frank C. Bennett, EVP and Chief Scientific Officer, reported acquiring 110 shares of common stock on August 31, 2026 through the company’s Amended and Restated 2000 Employee Stock Purchase Plan at $51.306 per share. After this purchase, he directly holds 60,128 shares of Ionis common stock. The filing states these purchased shares may not be sold until February 28, 2027, and no Rule 10b5-1 trading plan is reported for this transaction.
IONIS PHARMACEUTICALS INC (IONS) reported that executive vice president, chief legal officer and general counsel Patrick R. O'Neil acquired 63 shares of common stock on August 31, 2026 through the company’s employee stock purchase plan at $51.306 per share. Following this purchase, he directly holds 59,205 shares. According to the plan terms described, these 63 shares may not be sold until February 28, 2027, and the filing does not indicate that the transaction was made under a Rule 10b5-1 trading plan.
IONIS PHARMACEUTICALS INC (IONS) reports that Chief Executive Officer and director Brett P. Monia acquired 98 shares of common stock on August 31, 2026 through the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan at $51.306 per share. After this transaction, Monia directly holds 242,760 shares of Ionis common stock. According to the plan terms, these 98 shares may not be sold until February 28, 2027. No Rule 10b5-1 trading plan is reported for this transaction.
IONIS PHARMACEUTICALS INC (IONS) reports that executive vice president Brian Birchler acquired 58 shares of common stock on August 31, 2026 through the company’s Amended and Restated 2000 Employee Stock Purchase Plan at $51.306 per share.
The footnote states these shares may not be sold until February 28, 2027. Following this transaction, Birchler directly holds 102,883 shares of Ionis common stock.
IONIS PHARMACEUTICALS INC director Michael R. Hayden reported two open-market purchases of common stock by Genworks 2 Consulting, Inc., an entity through which his spouse holds shares with sole voting and investment power. Genworks 2 acquired 15,000 shares on July 30, 2026 at a weighted-average price of $53.38 and 5,000 shares on July 31, 2026 at a weighted-average price of $51.60, for a total of 20,000 additional indirectly held shares. Hayden also reports direct ownership of 54,298 Ionis common shares.
Ionis Pharmaceuticals reported Q2 2026 revenue of $267.9 million, down from $452.0 million a year earlier as prior-year collaboration upfronts did not repeat. Commercial revenue grew 15% to $118.6 million, led by DAWNZERA and early TRYNGOLZA sales. The company posted a net loss of $114.6 million versus prior-year profit of $123.6 million, as operating expenses rose with multiple launches.
For the first half of 2026, revenue was $514.0 million and net loss $207.2 million. Cash and cash equivalents were 350,065 (in thousands) and short-term investments 1,704,520 (in thousands) at June 30. The company repaid $432.5 million of 0% 2026 notes while continuing significant R&D investment. The FDA approved TRYNGOLZA for severe hypertriglyceridemia, while a Phase 3 ATTR‑CM trial of eplontersen missed its primary endpoint. Multiple partners paid milestones contributing approximately $180 million of R&D revenue in the half.